ARCTライブシグナル | Getagraph.comで利益を最大化

買う 107802 min ago

@ $38.32

発行日: 15 2月 2024 @ 05:08

リターン: -28.91%

前回のシグナル: 2月 14 - 05:48

前回のシグナル: 売る

リターン: -0.52 %

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:51):

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States...

Stats
本日の出来高	71 888.00
平均出来高	486 820
時価総額	733.17M
EPS	$0 ( 2024-03-07 )
次の収益日	( $-1.190 ) 2024-06-13
Last Dividend	$0.0596 ( 2013-01-08 )
Next Dividend	$0 ( N/A )
P/E	-24.32
ATR14	$0.0510 (0.19%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-25	Chivukula Pad	Sell	17 435	Common Stock
2024-03-19	Chivukula Pad	Sell	8 565	Common Stock
2023-12-15	Sassine Andy	Buy	75 000	Employee Stock Option (right to buy)
2023-12-15	Chivukula Pad	Buy	125 000	Employee Stock Option (right to buy)
2023-12-15	Kurata Lance	Buy	75 000	Employee Stock Option (right to buy)

INSIDER POWER
78.05
Last 97 transactions
Buy: 2 555 134 \| Sell: 1 046 972

ボリューム相関

長: -0.09 (neutral)

短: 0.21 (neutral)

Signal:(55.475) Neutral

Arcturus Therapeutics 相関

10 最も正の相関
AVEO	0.955
ITMR	0.949
RBNC	0.939
HEAR	0.932
SUMR	0.929
FCBP	0.92
DVCR	0.92
RMRM	0.918
AMYT	0.917
EA	0.917

10 最も負の相関
SBNY	-0.929
IMV	-0.925
DPRO	-0.92
NDRA	-0.913
MNDO	-0.91
CLDX	-0.909
SSPK	-0.909
WABC	-0.908
DFFN	-0.907
TCBC	-0.907

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Arcturus Therapeutics 相関 - 通貨/商品

-0.05
( neutral )

0.06
( neutral )

0.00
( neutral )

-0.18
( neutral )

-0.04
( neutral )

0.23
( neutral )

Arcturus Therapeutics 財務諸表

Annual	2023
収益:	$157.75M
総利益:	$154.79M (98.13 %)
EPS:	$-1.120

FY	2023
収益:	$157.75M
総利益:	$154.79M (98.13 %)
EPS:	$-1.120

FY	2022
収益:	$205.76M
総利益:	$62.70M (30.48 %)
EPS:	$0.350

FY	2021
収益:	$12.36M
総利益:	$0.00 (0.00 %)
EPS:	$-7.74

Financial Reports:

No articles found.

Arcturus Therapeutics Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Arcturus Therapeutics Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 1.571 - low (50.00%) | Divividend Growth Potential Score: 0 - No dividend growth expected in the near future

Information

First Dividend	$0.0200	2012-03-06
Last Dividend	$0.0596	2013-01-08
Next Dividend	$0	N/A
Payout Date	2013-01-15
Next Payout Date	N/A
# dividends	12	--
Total Paid Out	$0.679	--
Avg. Dividend % Per Year	0.00%	--
Score	2.12	--
Div. Sustainability Score	1.571
Div.Growth Potential Score	0
Div. Directional Score	0	--

Next Divdend (Est)
(2024-06-18)

$0 Estimate 0.00 %

Dividend Stability

0.02 Very Bad

Dividend Score

2.12

Pay Frequency

Monthly

Yearly Payout

Year	Amount	Yield
2012	$0	0.00%
2013	$0.119	0.23%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
OXLC	Dividend Royal	2023-12-14	Monthly	14	10.00%	8.50
OXSQ	Dividend Diamond	2023-12-14	Monthly	21	9.10%	8.50
HRZN	Dividend King	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	-0.165	1.500	-3.31	-4.96	[0 - 0.5]
returnOnAssetsTTM	-0.0619	1.200	-2.06	-2.48	[0 - 0.3]
returnOnEquityTTM	-0.0907	1.500	-2.12	-3.18	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	4.72	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	4.62	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	4.23	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.0704	-1.500	8.83	-10.00	[0 - 0.6]
interestCoverageTTM	-92.63	1.000	-10.00	-10.00	[3 - 30]
operatingCashFlowPerShareTTM	-0.677	2.00	-0.226	-0.451	[0 - 30]
freeCashFlowPerShareTTM	-0.784	2.00	-0.392	-0.784	[0 - 20]
debtEquityRatioTTM	0.108	-1.500	9.57	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.341	1.000	7.65	7.65	[0.2 - 0.8]
operatingProfitMarginTTM	-0.442	1.000	-10.00	-10.00	[0.1 - 0.6]
cashFlowToDebtRatioTTM	-0.596	1.000	-4.42	-4.42	[0.2 - 2]
assetTurnoverTTM	0.375	0.800	-0.836	-0.668	[0.5 - 2]
Total Score				1.571

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	-26.59	1.000	-2.79	0	[1 - 100]
returnOnEquityTTM	-0.0907	2.50	-1.362	-3.18	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.784	2.00	-0.261	-0.784	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	-0.677	2.00	-0.226	-0.451	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-0.444	1.500	-6.29	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	-0.112	1.000	-5.30	0	[0.1 - 0.5]
Total Score				-2.19

Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.